Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, Harris PA, Wong A, Lalani AS, Twelves CJ.
Albertella MR, et al.
Clin Cancer Res. 2008 Feb 15;14(4):1096-104. doi: 10.1158/1078-0432.CCR-07-4020.
Clin Cancer Res. 2008.
PMID: 18281542
Free article.
Clinical Trial.